Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 24

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 24
---
, defines the term “material breach” as a breach, with regards to which, it may be assumed that a reasonable
person would not have entered into the specific agreement had that person foreseen the breach and the outcome thereof, or a breach which
is specifically defined as material in the agreement. Acts that may constitute a material breach of the license agreement by us may include,
for example: the granting of sublicenses not in compliance with the provisions of the license agreement, a breach of our obligations to
pay required license payments or royalties and provide the necessary reports with respect thereto, a breach of our obligations not to
disclose or misuse certain confidential information of Yissum, and a breach of our obligations to develop and commercialize the Licensed
Technology (including our obligation to fund certain research and development activities) and to conduct patent prosecution and maintenance.

Our Chief Financial Officer may face competing demands on his time and attention.

Our Chief Financial Officer,
Arie Gordashnikov, plans to devote time to our business, but does not intend to focus exclusively on us. Mr. Gordashnikov also serves
in the same capacity for other companies. He may divide his time among these entities and us. Because our Chief Financial Officer manages
other businesses, he will not fully dedicate himself to advancing our business, financial condition, or operational results which could
hurt our business, financial condition and results of operations.

We are dependent upon our officers and directors and their loss, or a reduction in the amount of time they can dedicate to our initial business combination, could adversely affect our ability to operate.

Our operations are dependent
upon a relatively small group of individuals and, in particular, our officers and directors. We believe that our success depends on the
continued service of our officers and directors. In addition, our officers and directors are not required to commit any specified amount
of time to our affairs and, accordingly, will have conflicts of interest in allocating their time among various business activities, including
identifying potential business combinations and monitoring the related due diligence. We do not have key-man insurance on the life
of, any of our directors or officers. The unexpected loss of the services of one or more of our directors or officers could have a detrimental
effect on us.

<div align='center'>11</div>

The competitive landscape is highly dynamic, with continuous advancements in science and technology leading to the emergence of novel therapeutic modalities. Regulatory approvals, strategic partnerships, and market adoption of competing therapies could significantly impact the commercial potential of